Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

GW Pharma receives Czech approval for Sativex spray for MS

GW Pharma receives Czech approval for Sativex spray for MS

GW Pharmaceuticals (LON:GWP) this morning said its cannabis-derived spray has been approved in the Czech Republic for patients with multiple sclerosis.

After a protracted regulatory sign off her in the UK, Sativex was given the green light in six other European countries including Germany, Italy and Sweden last month under an EU mutual recognition pact.

Launch timing in each country will be dependent on national regulations concerning pricing and reimbursement. 

GW's marketing partner, Almirall, anticipates Sativex will launch in Germany, Denmark and Sweden before the year-end.

The endorsement of its efforts came earlier this week when it unveiled a landmark agreement with Novartis to sell the product in a number of overseas markets.

City broker Peel Hunt said GW could not have chosen a better partner than the Franco-Swiss drugs giant. 

Novartis recently gained US and European regulatory approval for the first oral MS treatment, Gilenya, which analysts believe could make $3 billion in peak annual sales.

Setting a 178 pence a share price target, Peel Hunt analyst Paul Cuddon told investors: “(We) see an excellent buying opportunity given the recent share price weakness.”

In the year to date the shares have fallen 6 per cent and closed last night at 108.5 pence, valuing the GW at £143 million. 

Sativex is currently undergoing phase III clinical development for the treatment of cancer pain.

View full GWP profile View Profile

GW Pharmaceuticals Timeline

Related Articles

April 19 2018
US food and drug administration approval isn't there yet, but Motif continues to chug forwards
August 22 2018
So far, the hit rate is a five out of 12 success rate for its investments
nizoral shampoo
June 19 2018
The new product will be the company's fourth international star brand

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use